Citadel Advisors’s Damora Therapeutics DMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-4
Closed -$47 – 14580
2024
Q2
$47 Sell
4
-4
-50% -$63 ﹤0.01% 14114
2024
Q1
$156 Buy
+8
New +$142 ﹤0.01% 14407
2023
Q3
– Sell
-112
Closed -$7.06K – 14590
2023
Q2
$7.06K Buy
112
+72
+180% +$3.92K ﹤0.01% 13390
2023
Q1
$1.99K Buy
+40
New +$2.11K ﹤0.01% 14225

Other funds holding DMRA

Citadel Advisors's DMRA Position: Q3 2026 in Review

Citadel Advisors increased its Damora Therapeutics (DMRA) stake by 133% in Q3 2026, buying an estimated $6.27M and bringing the position to 388,042 shares worth $8.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3957.

Citadel Advisors first reported a position in DMRA in Q1 2023 and has held it in 7 quarters since. 115 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

  • Citadel Advisors held 388,042 shares of Damora Therapeutics worth $8.26M as of Q3 2026.
  • Citadel Advisors bought 221,695 Damora Therapeutics shares in Q3 2026, an estimated $6.27M.
  • Damora Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #3957 holding.
  • Citadel Advisors first reported a position in Damora Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • 115 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.